Current News

Print version | Send article | RSS feed

Stratagene and Merck Subsidiary, Rosetta Inpharmatics, enter into joint development and license agreement
Development of RNA Purification System for Use in Molecular Diagnostics and Research Applications

16 Aug 2006 - Stratagene Corporation has entered into a joint development and license agreement with Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc., to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. Nucleic acid purification allows researchers to separate RNA contained in biological samples. Clinicians and researchers can use the purified RNA to perform gene expression analysis and other functions within molecular diagnostics.
 
Under the terms of the agreement, Stratagene and Rosetta will jointly develop a proprietary instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene's current customer base and companies engaged in pharmacogenomics. Financial terms of the agreement were not disclosed.